Skip to main content
Journal of Open Innovation: Technology, Market, and Complexity

Table 13 David Weiler’s royalty rate based on 458 deals in the pharma/biotech license agreement (Source: www.royaltysource.com) (IPRA Inc 2012)

From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies

485 deals

Rate

Average royalty

7 %

Median royalty

5 %

Maximum royalty

50 %

Minimum royalty

0 %

Back to article page